The Absorb IV Randomized Controlled Trial (RCT) is a clinical study designed to evaluate the safety and effectiveness of the Absorb™ Bioresorbable Vascular Scaffold (BVS) compared to the XIENCE stent. This trial is a continuation of the ABSORB III trial and includes approximately 2610 subjects from around 140 sites in and outside the United States. The primary objective is to compare the 30-day and long-term clinical outcomes of Absorb BVS to XIENCE in patients with ischemic heart disease caused by up to three new coronary artery lesions. The trial will also assess the incidence of angina and patient-reported outcomes over five years.